Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3053102 · 1 trial · 1 indication
A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| Arm | Type | Description |
|---|---|---|
| LY3053102 | EXPERIMENTAL | A single 2-, 7-, 20-, 50-, 150-, or 405-milligrams (mg) dose of LY3053102 was subcutaneously administered to newly randomized participants in 6 escalating dose level cohorts. The dose was escalated based on the safety results over at least a 7-day evaluation period postdose. The dose escalation occurred over 13 weeks proceeding according to tolerability at each dose level. |
| Placebo | PLACEBO_COMPARATOR | A single dose of LY3053102-matching placebo was administered subcutaneously to 1 newly randomized participant in each LY3053102-dose level cohort over 13 weeks. |
| Name | Type | Description |
|---|---|---|
| LY3053102 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Normal blood pressure * Female participants were not of child-bearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause * Had a body mass index (BMI) of 18.5 to 40.0 kilograms per square meter (kg/m\^2), inclusive, ...
LY3053102 is an investigational small molecule developed by Eli Lilly and Company. It has been studied in a Phase 1 clinical trial in healthy adult volunteers. The specific disease or condition it is intended to treat has not been publicly disclosed.
LY3053102 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. The compound is an investigational small molecule that has completed a Phase 1 study in healthy participants.
LY3053102 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. The study was a randomized, double-blind, placebo-controlled trial conducted in Singapore.
LY3053102 has been evaluated in one completed Phase 1 trial, NCT01736241, titled A Study of LY3053102 in Healthy Participants. The trial enrolled 41 healthy volunteers in Singapore and used a randomized, double-blind, placebo-controlled design.
LY3053102 is not approved. It is an investigational small molecule that has completed a single Phase 1 clinical trial in healthy volunteers. No regulatory approval has been granted for this compound.